An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)
Conditions
Interventions
- DRUG: LUM001 (Maralixibat)
Sponsor
Mirum Pharmaceuticals, Inc.